dm+d
Unassigned
New Medicines
Chronic hand eczema (CHE)
Information
New molecular entity
Leo Pharma
Leo Pharma
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials
Category
Topical pan-Janus kinase (JAK)-inhibitor
CHE is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. It is the most common skin disorder of the hands that affects an estimated 1 – 5% of the general population with a one-year prevalence rate of approximately 10%. It is an inflammatory, non-infectious skin disorder of the hands and wrists4,9 and can cause itching, blisters, swelling and pain [1].
Chronic hand eczema (CHE)
Topical